630 related articles for article (PubMed ID: 25932951)
1. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.
Sanzey M; Abdul Rahim SA; Oudin A; Dirkse A; Kaoma T; Vallar L; Herold-Mende C; Bjerkvig R; Golebiewska A; Niclou SP
PLoS One; 2015; 10(5):e0123544. PubMed ID: 25932951
[TBL] [Abstract][Full Text] [Related]
2. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.
Abdul Rahim SA; Dirkse A; Oudin A; Schuster A; Bohler J; Barthelemy V; Muller A; Vallar L; Janji B; Golebiewska A; Niclou SP
Br J Cancer; 2017 Sep; 117(6):813-825. PubMed ID: 28797031
[TBL] [Abstract][Full Text] [Related]
3. A Large-Scale RNAi Screen Identifies SGK1 as a Key Survival Kinase for GBM Stem Cells.
Kulkarni S; Goel-Bhattacharya S; Sengupta S; Cochran BH
Mol Cancer Res; 2018 Jan; 16(1):103-114. PubMed ID: 28993509
[TBL] [Abstract][Full Text] [Related]
4. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
5. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme.
Wolf A; Agnihotri S; Munoz D; Guha A
Neurobiol Dis; 2011 Oct; 44(1):84-91. PubMed ID: 21726646
[TBL] [Abstract][Full Text] [Related]
6. The angiogenic switch leads to a metabolic shift in human glioblastoma.
Talasila KM; Røsland GV; Hagland HR; Eskilsson E; Flønes IH; Fritah S; Azuaje F; Atai N; Harter PN; Mittelbronn M; Andersen M; Joseph JV; Hossain JA; Vallar L; Noorden CJ; Niclou SP; Thorsen F; Tronstad KJ; Tzoulis C; Bjerkvig R; Miletic H
Neuro Oncol; 2017 Mar; 19(3):383-393. PubMed ID: 27591677
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Said HM; Hagemann C; Carta F; Katzer A; Polat B; Staab A; Scozzafava A; Anacker J; Vince GH; Flentje M; Supuran CT
Bioorg Med Chem; 2013 Jul; 21(13):3949-57. PubMed ID: 23706268
[TBL] [Abstract][Full Text] [Related]
8. Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations.
Martell E; Kuzmychova H; Senthil H; Kaul E; Chokshi CR; Venugopal C; Anderson CM; Singh SK; Sharif T
Acta Neuropathol Commun; 2023 Jul; 11(1):110. PubMed ID: 37420311
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: a new target gleaned from an old concept.
Yuen CA; Asuthkar S; Guda MR; Tsung AJ; Velpula KK
CNS Oncol; 2016; 5(2):101-8. PubMed ID: 26997129
[TBL] [Abstract][Full Text] [Related]
10. Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).
Demeure K; Fack F; Duriez E; Tiemann K; Bernard A; Golebiewska A; Bougnaud S; Bjerkvig R; Domon B; Niclou SP
Mol Cell Proteomics; 2016 Feb; 15(2):481-92. PubMed ID: 26243272
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas.
Miranda-Gonçalves V; Granja S; Martinho O; Honavar M; Pojo M; Costa BM; Pires MM; Pinheiro C; Cordeiro M; Bebiano G; Costa P; Reis RM; Baltazar F
Oncotarget; 2016 Jul; 7(29):46335-46353. PubMed ID: 27331625
[TBL] [Abstract][Full Text] [Related]
12. Passenger deletions generate therapeutic vulnerabilities in cancer.
Muller FL; Colla S; Aquilanti E; Manzo VE; Genovese G; Lee J; Eisenson D; Narurkar R; Deng P; Nezi L; Lee MA; Hu B; Hu J; Sahin E; Ong D; Fletcher-Sananikone E; Ho D; Kwong L; Brennan C; Wang YA; Chin L; DePinho RA
Nature; 2012 Aug; 488(7411):337-42. PubMed ID: 22895339
[TBL] [Abstract][Full Text] [Related]
13. Glucose-6-phosphatase is a key metabolic regulator of glioblastoma invasion.
Abbadi S; Rodarte JJ; Abutaleb A; Lavell E; Smith CL; Ruff W; Schiller J; Olivi A; Levchenko A; Guerrero-Cazares H; Quinones-Hinojosa A
Mol Cancer Res; 2014 Nov; 12(11):1547-59. PubMed ID: 25001192
[TBL] [Abstract][Full Text] [Related]
14. NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme.
Hsieh CH; Wu CP; Lee HT; Liang JA; Yu CY; Lin YJ
Free Radic Biol Med; 2012 Aug; 53(4):649-58. PubMed ID: 22713363
[TBL] [Abstract][Full Text] [Related]
15. Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma.
Mao P; Hever-Jardine MP; Rahme GJ; Yang E; Tam J; Kodali A; Biswal B; Fadul CE; Gaur A; Israel MA; Spinella MJ
PLoS One; 2013; 8(11):e81803. PubMed ID: 24312360
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells.
Mughal AA; Grieg Z; Skjellegrind H; Fayzullin A; Lamkhannat M; Joel M; Ahmed MS; Murrell W; Vik-Mo EO; Langmoen IA; Stangeland B
Mol Cancer; 2015 Aug; 14():160. PubMed ID: 26292663
[TBL] [Abstract][Full Text] [Related]
18. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia.
Hofstetter CP; Burkhardt JK; Shin BJ; Gürsel DB; Mubita L; Gorrepati R; Brennan C; Holland EC; Boockvar JA
PLoS One; 2012; 7(1):e30059. PubMed ID: 22253878
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of carbohydrate sulfotransferase 12 decreases the proliferation and mobility of glioblastoma cells via the WNT/β-catenin pathway.
Wang J; Xia X; Tao X; Zhao P; Deng C
Bioengineered; 2021 Dec; 12(1):3934-3946. PubMed ID: 34288811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
